From regulatory approval to clinical practice: real-world eligibility for anti-amyloid monoclonal antibodies in an Italian dementia-care network
Authors:
- Giovanna ZamboniGZGiovanna Zamboni
- Manuela TondelliMTManuela Tondelli
- Giulia VincetiGVGiulia Vinceti
- Chiara GallinganiChiara Gallingani
- Zeno BerciniZBZeno Bercini
- Aurora BarbieriABAurora Barbieri
- Chiara CarboneCCChiara Carbone
- Najara IacovinoNINajara Iacovino
- Silvia CossuttiSCSilvia Cossutti
- Daniela BallottaDBDaniela Ballotta
- Simone SalemmeSSSimone Salemme
- Annalisa ChiariACAnnalisa Chiari
Open Access
- 13 August 2026
- journal article
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (9)
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinicThe Journal Of Prevention of Alzheimer's Disease, 2026
- Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer’s diseaseNeurological Sciences, 2025
- Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinicsThe Journal Of Prevention of Alzheimer's Disease, 2025